A pair of cases from Academy 2026 show scleral lens refits for severe keratoconus, one addressing focal corneal edema and one fitting around glaucoma tube shunts.

Eric Schmidt, OD, FAAO, presented his poster "Patient-Reported Blurred Vision Improvement with Cyclosporine 0.1%/PFBP in Dry Eye Disease with Severe Central Corneal Staining: Phase 3 Pool" at AAOpt 2026.

Raman Bhakhri, OD, FAAO, details a session given with Denise Skiadopoulos, OD, FAAO, during the annual AAOpt meeting in Anaheim, California.

Dry eye questionnaires capture only 22.4% of Demodex blepharitis symptoms, and a 22-study review links Demodex infestation to worse meibomian gland function.

Shane Kannarr, OD, overviews results from a phase 4, multicenter, prospective, open-label trial that evaluated the impact of concomitant use of PFHO during contact lens wear.

Real-world PFHO data show OSDI scores falling within 2 weeks, while a 12-month trial finds stable corneal endothelial cell density with cyclosporine 0.1%.

Christopher W. Lievens, OD, MS, PhD, FAAO, FNAP, FBCLA, discusses his poster presentation titled "Latanoprostene bunod 0.024% Initiation in Medicare Fee-for-Service Patients with Open Angle Glaucoma and Ocular Hypertension."

Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.